Family Pharmacist System for Patients With Chronic Cardiovascular or Endocrine Disease

Is the use of a family pharmacist system associated with lower risk of death or hospitalization among older patients with chronic cardiovascular or endocrine disease?In this cohort study including 45 114 users and nonusers of the system, there was no difference in the composite end point of death or hospitalization between users and nonusers. However, users had a slightly but significantly lower risk of death than nonusers (33.9 vs 37.0 deaths per 1000 person-years), with no significant difference in hospitalization risk.Findings suggest that the family pharmacist system is associated with slightly fewer deaths among older patients with chronic diseases, although confirmation of a causal effect of the system on mortality will be required.

Corresponding Author: Ryo Iketani, PhD, Division of Pharmacoepidemiology, Showa Medical University Graduate School of Pharmacy, 1-5-8 Hatanodai, Shinagawa, Tokyo 142-8555, Japan (iketani.research@gmail.com).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.